TechBio News 🪩 (III)
Latest Trends: Aimble, AI Proteins, Psivant Therapeutics, Nabla Bio, Arpeggio BioSciences, Nano-X Vision, WhiteLab Genomics and Almirall
This is part III of today’s Weekly TechBio newsletter.
Latest Trends: Latent Labs, Algorithmiq, NVIDIA, eXoZymes, Agilisium, ABVC and BioKey, Hill Research and Aikium
Latest Trends: Cosmo Pharmaceuticals, SandboxAQ, drug2drugs by Fujifilm, Coeptis Therapeutics, Insilico Medicine, Charles River and Vamstar
▶️ TechBio News (III)
Latest Trends: Aimble, AI Proteins, Psivant Therapeutics, Nabla Bio, Arpeggio BioSciences, Nano-X Vision, WhiteLab Genomics and Almirall
🌀 Nina Capital | Investing in Health Tech
Nina Capital just secured (February 12, 2025) €50M to support early-stage #HealthTech startups tackling the future of medicine.
TechBio News (III)
🪩 Aimble Also Known As 에임블, Legal Name 사랑스러운
Aimble founded in 2020 in Seoul has developed a structure-based in-silico drug discovery platform utilizing AI, docking, molecular dynamics and quantum computing. They are implementing a fast and accurate CADD (Computer-Aided Drug Design) process to maximize the efficiency of early drug development and they have established a synthesis research institute, providing drug design and synthesis as a one-stop service. Their automated drug screening platform based on molecular dynamics and AI, is binding force prediction and toxicity prediction. At the same time, in order to improve the accuracy of Aimble's DL model, the company is continuing to accumulate high-quality data generated from quantum calculations and molecular dynamics calculations.
The CEO is Kim Hyun-jin and the company had a Seed investment back in November 2020 (New Paradigm) and also attracted a Pre-A investment in May 2022 (Schmidt, Donghoon Investment).
Currently, Aimble is developing a vaccine library using advanced AI technology in collaboration with VAXDIGM (신·변종 바이러스 대응 신속 백신 및 항노화 치료용 백신 등 개발 계획, Development plan for rapid vaccines to respond to new and variant viruses and vaccines for anti-aging treatment). Vaxdigm Co., Ltd (백스다임) based in Seoul, South Korea and founded in 2021 by Seung-Hoo Kim (CTO), is a biotechnology company focused on the research and development of vaccines.
In particular, the two companies agreed in 2024 to jointly discover new drug and vaccine candidates and to cooperate in the rapid development of various vaccines with improved safety, stability and efficacy utilizing AI. Therefore, Vaxdigm plans to actively utilize cutting-edge AI technologies together with Aimble to rapidly develop vaccines for new and mutated viruses that could cause future pandemics, such as universal flu vaccines and anti-aging vaccines, as well as a vaccine library to prepare for pandemic situations.